[Initial experiences with a nation-wide Austrian study of adjuvant chemo- and immunotherapy of colorectal cancer following radical surgery].
The outline of a cooperative study for adjuvant Chemo-Immunotherapy on radically operated Colon-Rectum-Carcinoma, is presented. One group of patients receiving Placebo, has to be randomized against another group who postoperatively received Chemo-Immunotherapy consisting of 5-Fluorouracil and CCNU and Corynebacterium parvum, which was administered intermittently, throughout one year. Patients with Rectum-Carcinoma additionally receive radio-therapy with 1500 rad HD before surgery and 4500--5000 rad HD postoperatively with Cobalt-60. The central documentation, and randomization, is provided at the Institute for Cancer Research of the University of Vienna.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001317:Austria; D003082:Colectomy; D003110:Colonic Neoplasms / Q000628:therapy*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D011425:Propionibacterium acnes / Q000276:immunology; D012004:Rectal Neoplasms / Q000628:therapy*; D012007:Rectum / Q000601:surgery; D012673:Semustine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D012673:Semustine; D005472:Fluorouracil
Erste Erfahrungen einer gesamtösterreichischen Studie zur adjuvanten Chemo- und Immunotherapie des radikal operierten Colon-Rektum-Karzinoms.